Generative Artificial Intelligence in the Pharmaceutical
Generative Artificial Intelligence in the Pharmaceutical
https://www.openpr.com/news/4517653/generative-artificial-intelligence-in-the-pharmaceutical
Publish Date: 2026-05-19 00:03:00
Source Domain: www.openpr.com
- Market Growth Projection: The market for generative AI in pharmaceuticals is projected to reach $9.36 billion by 2030, with a compound annual growth rate (CAGR) of 30.9%, driven by advancements in AI algorithms and the adoption of precision medicine.
- Key Players: Major companies like Pfizer Inc., Johnson & Johnson, Roche Holding AG, and others are leading innovations in the generative AI pharmaceutical market.
- Collaborative Initiatives: In 2023, Eli Lilly and Company partnered with XtalPi Inc. to leverage advanced AI platforms for faster, more accurate drug candidate design and development.
- Emerging Technologies: Companies like Nvidia are introducing generative AI microservices to streamline drug discovery, medical imaging, and diagnostics with applications such as advanced imaging and digital biology capabilities.
- Market Segmentation: The generative AI market is segmented by type (small/large molecule), technology (deep learning, NLP, etc.), and application (clinical trials, drug discovery), highlighting various specific uses and methodologies.
